Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

  • Biotechnology
  • Cannabis
  • Cancer

He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

Read

Commented by Stefan Feulner on February 1st, 2023 | 20:29 CET

BioNTech, Defence Therapeutics, PAION - All dams broken

  • Biotechnology

High price fluctuations due to approvals or successful test results are more the norm than the rule in the biotechnology sector. It is common for smaller stocks, in particular, to multiply within a few days. For example, the shares of Ambrx Biopharma increased by a whopping 1,000% within just one day, while the German biotech hopeful PAION doubled in price within a week. The next candidates for above-average performances are already waiting in the wings.

Read

Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

  • Biotechnology
  • Cancer
  • Covid19
  • Investments

Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

Read

Commented by Fabian Lorenz on January 19th, 2023 | 11:24 CET

Nel after the ITM Power shock: Better to bet on BioNTech and Alpina Holdings?

  • Technology
  • Investments

The year 2022 was not the year of growth stocks. Will this change in 2023? The positive start to the current year shows that the chances of this happening are quite good; however, not in the hydrogen sector. The renewed warning from ITM Power is weighing on the entire sector and stoking fears that Nel, Plug Power & Co. will not be able to work off their full order books in 2023 either. That is where a look at other sectors and stocks can pay off. Example: Alpina Holdings from Singapore. The Company is growing at double-digit rates, and its valuation is incredibly low. BioNTech wants to expand further. Goldman Sachs expects strong newsflow from the cancer pipeline in 2023.

Read

Commented by Armin Schulz on January 9th, 2023 | 17:35 CET

BioNTech, Defence Therapeutics, Bayer - Is a Corona tsunami imminent?

  • Biotechnology
  • Covid19
  • Cancer

At the beginning of December, things were quiet concerning Corona. The feared wave failed to materialize, and there were no new variants. On December 7, China announced a relaxation of Corona measures. Now the country is facing a gigantic Corona wave. Many European countries have already imposed mandatory testing for entry from China. Germany has now followed suit. In parallel, the Consumer Electronics Show 2023 ran from the 5th to the 8th in Las Vegas, where all kinds of companies from all over the world presented their latest technology. Chinese companies also exhibited there. Because of the multitude of infections, new deadly mutations could emerge. As a result, pharmaceutical and biotech companies are coming back into focus.

Read

Commented by André Will-Laudien on January 5th, 2023 | 06:35 CET

It is the year 2023 and COVID is back! BioNTech, Bayer, Defence Therapeutics, Morphosys - Which stocks stand up to the virus from China?

  • Biotechnology
  • Covid19
  • Cancer

The next COVID wave is raging in China. The situation is no less dramatic today than in 2019 because until now, only vaccines produced in the country may be administered to locals in China. Before Christmas, however, the German government obtained permission to have Germans in China vaccinated with the active ingredient from BioNTech and immediately had the first doses flown out to Beijing. Yesterday, the EU discussed a joint reaction to the current conditions in China. German medical officials are calling for mandatory Europe-wide testing of all people entering the country and are warning of a new, dangerous virus mutation due to the large numbers of infections. Investors are therefore taking the vaccine experts back into focus.

Read

Commented by Fabian Lorenz on January 4th, 2023 | 07:17 CET

Takeover fever 2023? BioNTech, Barrick Gold, Standard Lithium, Manuka Resources

  • Mining
  • Vanadium
  • Lithium
  • Biotechnology
  • Gold

The pharmaceutical sector was already in takeover fever last year. BioNTech partner Pfizer, among others, made several acquisitions. The hunger for acquisitions is likely to continue in the current year as major pharmaceutical and biotech companies are looking to fill up their pipelines. The current year could also be exciting for gold stocks. In 2022, companies failed to keep pace with the positive gold price. Producers of raw materials for the energy transition could also get into takeover fever. Manuka Resources could benefit from the latest two trends. The Canadians have just carried out a capital measure to advance their projects. Corporations could also target specialists like Standard Lithium. Rumours that Tesla is looking at lithium projects have been doing the rounds for a long time. And what about Barrick Gold and BioNTech?

Read

Commented by André Will-Laudien on January 3rd, 2023 | 07:26 CET

New COVID outbreak in China: BioNTech, Cardiol Therapeutics, CureVac and Valneva shares in focus again in 2023

  • Biotechnology
  • Covid19
  • heartdisease

The next COVID wave is rolling towards Europe. Representatives of the EU states therefore want to discuss a unified approach on Wednesday due to the latest development in China. The main issue is how to deal with entrants from China. A spokeswoman for the Federal Ministry of Health in Berlin said that the situation is being closely monitored and that the EU partners are also being consulted. At French airports, arrivals from China are already generally tested for the virus. Italy and Spain have also reacted with corresponding regulations. The German government sees no reason to do so so far. Is Germany too slow again, or is prudence the order of the day?

Read

Commented by Stefan Feulner on December 30th, 2022 | 17:52 CET

BioNTech, Defence Therapeutics, Pfizer - The cards are being reshuffled

  • Biotechnology
  • Covid19
  • Investments

The Corona pandemic is seemingly coming to an end after almost three long years. The return to normality, now in China and the rest of the world, is a relief for society and the economy. In contrast, vaccine manufacturers are losing a billion-dollar business that is difficult to compensate for with products in other areas of application. Nevertheless, the stock market valuations of the vaccine producers continue to be exorbitantly high, as does their drop in value.

Read

Commented by Fabian Lorenz on December 28th, 2022 | 08:05 CET

Outperformer stocks in 2023? BioNTech, Steinhoff, Saturn Oil + Gas, K+S

  • Mining
  • Oil
  • Gas
  • Biotechnology
  • fertilizer

Will energy stocks continue to be outperformers in 2023? In any case, in 2022, MSCI World Energy clearly outperformed MSCI World. In the case of individual stocks, Shell, for example, has gained over 45% in the current year. Jefferies recommends the stock as a buy with a target price of GPX 3100 (pence). Warren Buffett has also invested billions in the oil sector in 2022. Chevron and Occidental Petroleum are among Berkshire Hathaway's seven largest holdings. Energy, after all, is likely to be in demand in 2023. Those looking to bet on a laggard should look at Saturn Oil & Gas. The Canadian oil producer faces a milestone in 2023, and analysts see over 200% upside potential. BioNTech enters the new year with solid newsflow. And what is Steinhoff doing after the horror news?

Read